A multicentre, randomised, double-blind, placebo-controlled, multiple ascending dose, pilot phase 2a study determined that PRS-080 is safe in anaemic stage 5 chronic kidney disease patients requiring haemodialysis. A haemoglobin (Hb) response with clear segregation of Hb values between placebo and PRS-080 in the 8 mg/kg cohort during the treatment period showed early efficacy, consisting of an increase of Hb in drug-treated patients and a decline in placebo patients, potentially related to the withdrawal of iron treatment .
Nephrologist Prof. Lutz Renders (Klinikum Rechts der Isar, Germany) explained that patients with chronic kidney disease (CKD) commonly present with anaemia. Current treatment regimens consist of iron, erythropoietin stimulating agents (ESAs), or both, but a significant proportion of patients remain anaemic despite these therapies. Hepcidin, a liver...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Subcutaneous daratumumab + cyclophosphamide, bortezomib, and dexamethasone in patients with newly diagnosed amyloid light chain amyloidosis Next Article
Infectious complications mild and not common in patients receiving CAR-T therapy for diffuse large B cell lymphoma »
Table of Contents: EHA 2019
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.